Literature DB >> 2477656

Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation.

W P Sheridan1, G Morstyn, M Wolf, A Dodds, J Lusk, D Maher, J E Layton, M D Green, L Souza, R M Fox.   

Abstract

Granulocyte colony-stimulating factor (G-CSF) was administered by continuous subcutaneous infusion to 15 patients with non-myeloid malignancies treated by high-dose chemotherapy and autologous bone marrow infusion. G-CSF was given at variable dosage based on neutrophil count. Sustained serum levels of G-CSF were achieved. Neutrophil recovery was accelerated in G-CSF treated patients compared with 18 historical controls and exceeded 0.5 x 10(9)/l at a mean of 11 days after marrow infusion compared with 20 days for controls, a significant difference. This reduction led to significantly fewer days of parenteral antibiotic therapy, 11 versus 18 days in controls, and less isolation in reverse-barrier nursing, 10 versus 18 days.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2477656     DOI: 10.1016/s0140-6736(89)91552-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  58 in total

Review 1.  New perspectives in lung cancer. 4. Haematopoietic growth factors and lung cancer treatment.

Authors:  N Thatcher
Journal:  Thorax       Date:  1992-02       Impact factor: 9.139

Review 2.  G-CSF: status quo and new indications.

Authors:  F Herrmann
Journal:  Infection       Date:  1992 Jul-Aug       Impact factor: 3.553

Review 3.  Haematology.

Authors:  N T O'Connor
Journal:  Postgrad Med J       Date:  1990-08       Impact factor: 2.401

4.  Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.

Authors:  R J Lipsy
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

5.  Haemopoietic growth factors.

Authors:  A Khwaja; A H Goldstone
Journal:  BMJ       Date:  1991-05-18

6.  Therapeutic effect of granulocyte colony-stimulating factor and cephem antibiotics against experimental infections in neutropenic mice induced by cyclophosphamide.

Authors:  H Wakiyama; S Tsuru; N Hata; M Shinomiya; N Shinomiya; M Noritake; Y Umezawa; M Rokutanda
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

7.  Granulocyte colony-stimulating factor (G-CSF) as an adjunct to induction chemotherapy of adult acute lymphoblastic leukemia (ALL).

Authors:  R Scherrer; K Geissler; P A Kyrle; H Gisslinger; U Jäger; P Bettelheim; K Laczika; G Locker; C Scholten; C Sillaber
Journal:  Ann Hematol       Date:  1993-06       Impact factor: 3.673

Review 8.  Use and toxicity of the colony-stimulating factors.

Authors:  J R Schriber; R S Negrin
Journal:  Drug Saf       Date:  1993-06       Impact factor: 5.606

9.  Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon.

Authors:  E Roilides; K Uhlig; D Venzon; P A Pizzo; T J Walsh
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

10.  Optimal timing of granulocyte colony-stimulating factor (G-CSF) administration after bone marrow transplantation. A prospective randomized study.

Authors:  A Torres Gómez; M A Jimenez; M A Alvarez; A Rodriguez; C Martin; M J Garcia; R Flores; J Sanchez; M J de la Torre; C Herrera
Journal:  Ann Hematol       Date:  1995-08       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.